Randomized phase II study of S-1 dosing schedule for resected colorectal cancer
Chu Matsuda(Osaka International Cancer Institute), Masaki Mori(Tokai University), Mamoru Uemura(Osaka International Cancer Institute), Masayuki Ohue(Hyogo Medical University), Junichi Hasegawa(Osaka Rosai Hospital), Ichiro Takemasa(Osaka International University), Tsunekazu Mizushima(The University of Osaka), Yuichiro� Doki(Osaka Gakuin University), Mitsugu Sekimoto(Kansai Medical University), Taishi Hata(The University of Osaka), Taroh Satoh(Osaka University Hospital), Masataka Ikeda(Hyogo Medical University), Junichi Nishimura, Hirofumi Yamamoto(Osaka Gakuin University), Ken Nakata(Sakai Municipal Hospital), Takeshi Kato(Osaka National Hospital), Kohei Murata(Suita Municipal Hospital), Tatsushi Shingai(Kinki Central Hospital), Masakazu Ikenaga(Osaka National Hospital), Riichiro Nezu(Nishinomiya Municipal Central Hospital)
Cited by 2
Related Papers
Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab
|Science Translational Medicine|2011|670
Large-scale genome-wide association study in a Japanese population identifies novel susceptibility loci across different diseases
|Nature Genetics|2020|591
A Japanese Lung Cancer Registry Study: Prognosis of 13,010 Resected Lung Cancers
|Journal of Thoracic Oncology|2008|424